This report was first published by Endpoints News. To see the original version, click here
One of biotech’s best-funded startups plans to go public, as it seeks to take its obesity portfolio into a market crowded by Eli Lilly, Novo Nordisk and other next-generation obesity contenders.
Kailera Therapeutics filed for an IPO on Friday night, planning to trade on the Nasdaq under the ticker “KLRA.” The company has yet to disclose how much stock it hopes to sell, but in its relatively short life as a startup it’s already raised about $1 billion.
您已阅读20%（544字），剩余80%（2123字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。